LY-341,495 je istraživački lek koji deluje kao potentan i selektivan ortosterni antagonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3).[1][2][3][4]
1-fluorociklopropanski analog ima superiornifarmakokinetički profil i sličan mGluR2/3 afinitet.Prolek u obliku heptil estra ima poboljšanu bioadostupnost.[14]
^Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M.Journal of Medicinal Chemistry. 1998 Jan 29; .Ornstein, P. L.; Bleisch, T. J.; Arnold, M. B.; Kennedy, J. H.; Wright, R. A.; Johnson, B. G.; Tizzano, J. P.; Helton, D. R.; Kallman, M. J.; Schoepp, D. D.; Hérin, M. (1998). „2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.”.Journal of Medicinal Chemistry.41 (3): 358—78.PMID9464367.doi:10.1021/jm970498o..
^Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD, Kingston AE, Lodge D, Collingridge GL.Neuropharmacology. 1998 Dec; .Fitzjohn, S. M.; Bortolotto, Z. A.; Palmer, M. J.; Doherty, A. J.; Ornstein, P. L.; Schoepp, D. D.; Kingston, A. E.; Lodge, D.; Collingridge, G. L. (1998). „The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity”.Neuropharmacology.37 (12): 1445—58.PMID9886667.doi:10.1016/s0028-3908(98)00145-2.
^Pilc A, Chaki S, Nowak G, Witkin JM.Biochemical Pharmacology. 2008 Mar 1; .Pilc, A.; Chaki, S.; Nowak, G.; Witkin, J. M. (2008). „Mood disorders: regulation by metabotropic glutamate receptors”.Biochemical Pharmacology.75 (5): 997—1006.PMID18164691.doi:10.1016/j.bcp.2007.09.021.
^Matrisciano F, Panaccione I, Zusso M, Giusti P, Tatarelli R, Iacovelli L, Mathé AA, Gruber SH, Nicoletti F, Girardi P.Molecular Psychiatry. 2007 Aug; .Matrisciano, F.; Panaccione, I.; Zusso, M.; Giusti, P.; Tatarelli, R.; Iacovelli, L.; Mathé, A. A.; Gruber, S. H.; Nicoletti, F.; Girardi, P. (2007). „Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?”.Molecular Psychiatry.12 (8): 704—6.PMID17653204.doi:10.1038/sj.mp.4002005.
^Gewirtz JC, Marek GJ.Neuropsychopharmacology. 2000 Nov; .Gewirtz, J. C.; Marek, G. J. (2000). „Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors”.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology.23 (5): 569—76.PMID11027922.doi:10.1016/S0893-133X(00)00136-6.
^Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E.Molecular Pharmacology. 2007 Aug; .Benneyworth, M. A.; Xiang, Z.; Smith, R. L.; Garcia, E. E.; Conn, P. J.; Sanders-Bush, E. (2007). „A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.”.Molecular Pharmacology.72 (2): 477—84.PMID17526600.doi:10.1124/mol.107.035170.
^Chi H, Jang JK, Kim JH, Vezina P (2006). „Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine”.Neuropharmacology.51 (5): 986—92.PMID16901517.doi:10.1016/j.neuropharm.2006.06.008.
^Yoon HS, Jang JK, Kim JH (2008). „Blockade of group II metabotropic glutamate receptors produces hyper-locomotion in cocaine pre-exposed rats by interactions with dopamine receptors”.Neuropharmacology.55 (4): 555—9.PMID18675831.doi:10.1016/j.neuropharm.2008.07.012.
^Sakagami K; Yasuhara A; Chaki S; et al. (2008). „Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist”.Bioorg. Med. Chem.16 (8): 4359—66.PMID18348906.doi:10.1016/j.bmc.2008.02.066.CS1 одржавање: Експлицитна употреба et al. (веза)
Y
Podaci na Vikipodacima
